190 related articles for article (PubMed ID: 35718656)
1. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.
Mikamo H; Nagashima M; Kusachi S; Fujimi S; Oshima N; De Anda C; Takase A
J Infect Chemother; 2022 Sep; 28(9):1235-1241. PubMed ID: 35718656
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Wunderink RG; Roquilly A; Croce M; Rodriguez Gonzalez D; Fujimi S; Butterton JR; Broyde N; Popejoy MW; Kim JY; De Anda C
Clin Infect Dis; 2021 Aug; 73(3):e710-e718. PubMed ID: 33720350
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and pharmacokinetics of tedizolid versus linezolid in patients with skin and soft tissue infections in Japan - Results of a randomised, multicentre phase 3 study.
Mikamo H; Takesue Y; Iwamoto Y; Tanigawa T; Kato M; Tanimura Y; Kohno S
J Infect Chemother; 2018 Jun; 24(6):434-442. PubMed ID: 29530544
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
Lv X; Alder J; Li L; O'Riordan W; Rybak MJ; Ye H; Zhang R; Zhang Z; Zhu X; Wilcox MH
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988146
[TBL] [Abstract][Full Text] [Related]
5. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
[TBL] [Abstract][Full Text] [Related]
6. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
[TBL] [Abstract][Full Text] [Related]
7. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
Prokocimer P; De Anda C; Fang E; Mehra P; Das A
JAMA; 2013 Feb; 309(6):559-69. PubMed ID: 23403680
[TBL] [Abstract][Full Text] [Related]
8. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Leister-Tebbe H; Hill C; Geres H; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW;
Clin Infect Dis; 2024 Feb; 78(2):259-268. PubMed ID: 37740559
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
[TBL] [Abstract][Full Text] [Related]
10. Tedizolid: a new oxazolidinone antimicrobial.
Kisgen JJ; Mansour H; Unger NR; Childs LM
Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
[TBL] [Abstract][Full Text] [Related]
11. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
[TBL] [Abstract][Full Text] [Related]
12. Outpatient treatment of acute bacterial skin and skin structure infections (ABSSSI) with tedizolid phosphate and linezolid in patients in the United States: Subgroup analysis of 2 randomized phase 3 trials.
De Anda C; Anuskiewicz S; Prokocimer P; Vazquez J
Medicine (Baltimore); 2017 Dec; 96(52):e9163. PubMed ID: 29384903
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections.
Ortiz-Covarrubias A; Fang E; Prokocimer PG; Flanagan SD; Zhu X; Cabré-Márquez JF; Tanaka T; Passarell J; Fiedler-Kelly J; Nannini EC
Braz J Infect Dis; 2016; 20(2):184-92. PubMed ID: 26859064
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Timsit JF; Huntington JA; Wunderink RG; Shime N; Kollef MH; Kivistik Ü; Nováček M; Réa-Neto Á; Martin-Loeches I; Yu B; Jensen EH; Butterton JR; Wolf DJ; Rhee EG; Bruno CJ
Crit Care; 2021 Aug; 25(1):290. PubMed ID: 34380538
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P
Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472
[TBL] [Abstract][Full Text] [Related]
16. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.
Lodise TP; Fang E; Minassian SL; Prokocimer PG
Antimicrob Agents Chemother; 2014 Dec; 58(12):7198-204. PubMed ID: 25246392
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials.
Corey R; Moran G; Goering R; Bensaci M; Sandison T; De Anda C; Prokocimer P
Diagn Microbiol Infect Dis; 2019 Jul; 94(3):277-286. PubMed ID: 30940414
[TBL] [Abstract][Full Text] [Related]
18. The risk of inappropriate empiric treatment and its outcomes based on pathogens in non-ventilated (nvHABP), ventilated (vHABP) hospital-acquired and ventilator-associated (VABP) bacterial pneumonia in the US, 2012-2019.
Zilberberg MD; Nathanson BH; Puzniak LA; Dillon RJ; Shorr AF
BMC Infect Dis; 2022 Oct; 22(1):775. PubMed ID: 36199012
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections.
Bradley JS; Antadze T; Ninov B; Tayob MS; Broyde N; Butterton JR; Chou MZ; De Anda CS; Kim JY; Sears PS
Pediatr Infect Dis J; 2021 Mar; 40(3):238-244. PubMed ID: 33395210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
